See more : Vonovia SE (VNA.F) Income Statement Analysis – Financial Results
Complete financial analysis of Currenc Group, Inc. (CURR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Currenc Group, Inc., a leading company in the Financial – Credit Services industry within the Financial Services sector.
You may be interested
- PG Electroplast Limited (PGEL.NS) Income Statement Analysis – Financial Results
- NEC Networks & System Integration Corporation (NNSCF) Income Statement Analysis – Financial Results
- Berling S.A. (BRG.WA) Income Statement Analysis – Financial Results
- ISS A/S (ISFFF) Income Statement Analysis – Financial Results
- Nine Entertainment Co. Holdings Limited (NNMTF) Income Statement Analysis – Financial Results
Currenc Group, Inc. (CURR)
Industry: Financial - Credit Services
Sector: Financial Services
Website: https://investors.currencgroup.com/overview/default.aspx
About Currenc Group, Inc.
Currenc Group, Inc. engages in operating a fintech banking platform. It operates through the following segments: Remittance Services, Sales of Airtime, and Other Services. The company is headquartered in Singapore.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 53.26M | 4.90M | 6.56M | 2.05M | 623.00K | 583.94K | 180.40K | 84.17K | 183.43K | 251.83K |
| Cost of Revenue | 35.90M | 1.56M | 2.17M | 1.08M | 231.00K | 279.92K | 180.63K | 153.33K | 117.01K | 205.12K |
| Gross Profit | 17.36M | 3.34M | 4.38M | 975.00K | 392.00K | 304.02K | -225.00 | -69.17K | 66.42K | 46.71K |
| Gross Profit Ratio | 32.59% | 68.20% | 66.85% | 47.54% | 62.92% | 52.06% | -0.12% | -82.18% | 36.21% | 18.55% |
| Research & Development | 0.00 | 58.00K | 2.37M | 2.79M | 2.31M | 1.41M | 1.43M | 753.37K | 681.70K | 663.90K |
| General & Administrative | 23.98M | 7.94M | 18.88M | 11.37M | 10.12M | 6.45M | 0.00 | 0.00 | 0.00 | 914.74K |
| Selling & Marketing | 25.88K | 2.23M | 112.89K | 45.12K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 24.00M | 10.17M | 18.88M | 11.37M | 10.12M | 6.45M | 5.91M | 3.10M | 920.25K | 914.74K |
| Other Expenses | 1.00 | 99.00K | 2.04M | -9.32M | -575.00K | 393.41K | 30.83K | -106.78K | 105.73K | -990.81K |
| Operating Expenses | 24.00M | 11.73M | 21.25M | 14.15M | 12.43M | 7.86M | 7.34M | 3.86M | 1.60M | 587.83K |
| Cost & Expenses | 59.90M | 13.28M | 23.42M | 15.23M | 12.66M | 8.14M | 7.52M | 4.01M | 1.72M | 792.95K |
| Interest Income | 0.00 | 51.00K | 62.00K | 37.00K | 57.00K | 0.00 | 6.00 | 437.00 | 199.00 | 0.00 |
| Interest Expense | 8.00M | 465.00K | 554.00K | 2.47M | 4.11M | 3.04M | 1.58M | 121.57K | 173.46K | -84.84K |
| Depreciation & Amortization | 3.99M | 1.58M | 5.71M | -8.34M | 61.00K | 149.80K | 164.60K | 172.61K | 157.55K | 151.20K |
| EBITDA | -1.90M | -5.54M | 5.39M | -21.52M | -13.46M | -7.28M | -7.15M | -3.86M | -1.27M | -598.48K |
| EBITDA Ratio | -3.57% | -135.99% | -170.21% | -1,049.34% | -1,921.99% | -1,201.23% | -3,961.48% | -4,586.20% | -693.48% | -237.65% |
| Operating Income | -6.65M | -18.27M | -16.87M | -13.18M | -12.04M | -7.56M | -7.34M | -3.93M | -1.54M | -749.68K |
| Operating Income Ratio | -12.48% | -373.16% | -257.32% | -642.56% | -1,931.78% | -1,294.26% | -4,069.81% | -4,664.94% | -837.12% | -297.69% |
| Total Other Income/Expenses | -7.25M | -9.28M | -12.17M | -17.44M | -7.68M | -3.15M | -821.59K | -231.24K | -67.53K | 84.84K |
| Income Before Tax | -13.89M | -6.40M | -13.19M | -30.62M | -21.37M | -10.43M | -8.16M | -4.16M | -1.60M | -664.84K |
| Income Before Tax Ratio | -26.09% | -130.80% | -201.27% | -1,492.98% | -3,430.66% | -1,786.29% | -4,525.23% | -4,939.68% | -873.94% | -264.00% |
| Income Tax Expense | 523.48K | 42.00K | 2.60M | -6.85M | 3.53M | -30.47K | 1.60M | 14.80K | 279.20K | -84.84K |
| Net Income | -15.31M | -6.40M | -15.79M | -23.77M | -24.90M | -10.40M | -8.15M | -4.16M | -1.60M | -580.00K |
| Net Income Ratio | -28.74% | -130.80% | -240.85% | -1,159.14% | -3,996.63% | -1,781.07% | -4,517.57% | -4,939.68% | -873.94% | -230.31% |
| EPS | -0.97 | -0.09 | -0.33 | -0.50 | -0.72 | -0.42 | -0.34 | -0.18 | -0.06 | -0.02 |
| EPS Diluted | -0.33 | -0.09 | -0.33 | -0.50 | -0.72 | -0.42 | -0.34 | -0.18 | -0.06 | -0.02 |
| Weighted Avg Shares Out | 15.86M | 71.41M | 47.19M | 47.31M | 34.54M | 25.00M | 23.65M | 23.33M | 24.98M | 23.27M |
| Weighted Avg Shares Out (Dil) | 46.53M | 71.41M | 47.19M | 47.31M | 34.54M | 25.00M | 23.65M | 23.33M | 24.98M | 23.27M |
CURRENC Group Inc. Announces Third Quarter 2024 Unaudited Financial Results
SINGAPORE, Nov. 29, 2024 (GLOBE NEWSWIRE) -- CURRENC Group Inc. (Nasdaq: CURR) (“CURRENC” or the “Company”), a fintech and digital remittance pioneer serving millions of unbanked and underbanked individuals in Southeast Asia and beyond, recently announced its unaudited financial results...
CURRENC Rings Nasdaq Closing Bell in Honor of Listing
NEW YORK, Sept. 26, 2024 (GLOBE NEWSWIRE) -- CURRENC Group Inc. (Nasdaq: CURR) (“CURRENC” or the “Company”), a fintech and digital remittance pioneer serving millions of unbanked and underbanked individuals in Southeast Asia and beyond, today announced that the Company's...
Avenir Wellness Solutions Announces New Ticker Symbol As Final Part of Exciting New Brand Identity
New Branding Reflects Company's Commitment to the Future of Wellness SHERMAN OAKS, CA / ACCESSWIRE / August 8, 2023 / Avenir Wellness Solutions, Inc. (OTC Pink:CURR) ("Avenir" or the "Company"), a proprietary broad platform and wellness technology company, today announced...
Avenir Wellness Solutions (OTCQB:CURR) to Present at the Planet MicroCap Showcase - Live Webcast Available
Presentation TODAY at 1:30PM Pacific Time (4:30 PM Eastern Time) SHERMAN OAKS, CA / ACCESSWIRE / April 26, 2023 / Avenir Wellness Solutions, Inc. ("Avenir Wellness") (OTCQB:CURR), a proprietary broad platform technology and wellness company, announced today that it will...
Avenir Wellness Solutions to Present at Investor Summit Group's Q4 Conference
Sherman Oaks, California--(Newsfile Corp. - November 10, 2022) - Avenir Wellness Solutions, Inc. (f/k/a CURE Pharmaceutical Holding Corp.) (OTCQB: CURR) today announced that CEO Nancy Duitch will be attending the Q4 Investor Summit live in NYC at the Sheraton Times...
Cure Pharmaceutical Holding to Present at the LD Micro Main Event XV
Presentation on Tuesday, October 25 at 12:30 PM Pacific Time (3:30 PM Eastern)Oxnard, California--(Newsfile Corp. - October 24, 2022) - Cure Pharmaceutical Holding Corp. (OTCQB: CURR) ("CURE"), a broad wellness platform technology company that develops proprietary wellness, nutraceutical, and topical...
CURE Pharmaceutical Q2 2021 Revenue Spikes 700% After Increased Sales From Seba Labs Products Including A CVS Deal
Pharmaceutical company CURE Pharmaceutical Holding Corp. (OTC:CURR) announced earnings results on Tuesday for the quarter ended June 30, revealing revenue of $2.1 million. That's a year-over-year increase of 700%.
CURE Pharmaceutical to Present at H.C. Wainwright 2021 Psychedelics in Psychiatry and Beyond Virtual Conference
OXNARD, Calif.--(BUSINESS WIRE)--CURE Pharmaceutical Holding Corp. (OTC: CURR), a technology focused, vertically integrated drug delivery and product development company in the pharmaceutical and health & wellness markets, announced today that its Chief Business Officer Jonathan Berlent will participate in a...
Federally Compliant Medical Cannabis In The US? One Company Is Doing It
CURE Pharmaceutical (OTC:CURR) has signed an agreement with Biopharmaceutical Research Company (BRC) to produce federally compliant medical cannabis, CBD and THC products. BRC will provide the cannabinoid ingredients and CURE will use them to begin the development of CBD and...
CURE Pharmaceutical Signs Agreement to Develop CBD and THC Oral Thin Films and Conduct Clinical Studies Targeting Veteran Health
OXNARD, Calif.--(BUSINESS WIRE)--CURE Pharmaceutical Holding Corp. (OTC: CURR), a vertically integrated drug delivery and product development company, announced today that it has signed a partnership agreement with Biopharmaceutical Research Company, (BRC), an active Drug Enforcement Administration (DEA) license holder, to...
Source: https://incomestatements.info
Category: Stock Reports